Prevention of Clostridium difficile-associated disease

预防艰难梭菌相关疾病

• 批准号: 7480764
• 负责人: MYRON SASSER
• 金额: $ 9.92万
• 依托单位: MIDI, INC.
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-15 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7480764
• 关键词: Adjuvant; Alanine; Antibiotic Resistance; Antibiotic Therapy; Antibiotics; Bacteria; Clostridium difficile; Count; Data Collection; Diarrhea; Disease; Disinfectants; Elderly; Environment; Feasibility Studies; Gastrointestinal tract structure; Germination; Growth; Hospitals; In Vitro; Infection; Lead; Lecithin; Linolenic Acids; Metronidazole; Microscopic; Nosocomial Infections; Numbers; Oral; Patients; Phase; Phase-Contrast Microscopy; Prevention; Pseudomembranous Colitis; Public Health; Rate; Records; Relapse; Reproduction spores; Research; Residual state; Resistance; Small Business Funding Mechanisms; Small Business Innovation Research Grant; Staging; Symptoms; Testing; Time; TimeLine; Toxin; Vancomycin; concept; fluoroquinolone resistance; killings; mortality; pathogen; prevent; research study; time interval

DESCRIPTION (provided by applicant): Clostridium difficile-associated disease (CDAD) is a hospital-acquired problem following routine antibiotic treatment. Its impact may exceed that of any other nosocomial infection. Spores of the toxin-producing pathogen are highly resistant to antibiotics and therefore overgrow the gut when broad-spectrum oral antibiotics kill off the competing bacteria. The C. difficile spores are resistant to common hospital disinfectants, thus contaminating the hospital environment and providing inoculum for infection of patients, especially the highly vulnerable elderly. Disease symptoms include diarrhea and pseudomembranous colitis. Treatment of the disease is with metronidazole or vancomycin, but relapse is commonly more than 20%. Recent spread of a more aggressive strain, that produces toxins A and B at 16 times and 23 times greater, a binary toxins, is resistant to fluoroquinolones, is hyper-productive of spores, and leads to mortality rates greater than 16%. The proposed research is to develop adjuvants for routinely used antibiotics, enabling reduction of numbers of spores in the gut and subsequently inhibiting the germination and growth of C. difficile. The treatment should prevent C. difficile overgrowth of the GI tract, allowing competing bacteria to colonize the gut and suppress the growth of C. difficile and CDAD. PUBLIC HEALTH RELEVANCE: Clostridium difficile-associated disease (CDAD) is caused by antibiotic treatment and has become the most costly and injurious hospital-acquired infection. This SBIR research proposes prevention of CDAD through the use of adjuvants with the antibiotics.

描述（由申请方提供）：艰难梭菌相关疾病（CDAD）是常规抗生素治疗后的医院获得性问题。它的影响可能超过任何其他医院感染。产毒素病原体的孢子对抗生素具有高度耐药性，因此当广谱口服抗生素杀死竞争细菌时，孢子会在肠道中过度生长。梭艰难梭菌孢子对常用的医院消毒剂具有抗性，因此污染了医院环境，并为患者，特别是高度脆弱的老年人的感染提供了接种物。疾病症状包括腹泻和伪膜性结肠炎。该病的治疗是甲硝唑或万古霉素，但复发率通常超过20%。最近传播的一种更具侵略性的菌株，产生毒素A和B的16倍和23倍，二元毒素，对氟喹诺酮类药物有抗性，孢子高产，导致死亡率大于16%。拟议的研究是为常规使用的抗生素开发佐剂，从而减少肠道中的孢子数量，并随后抑制C。很难治疗应预防C.艰难梭菌的胃肠道过度生长，使竞争细菌定植肠道和抑制生长的C。difficile和CDAD。公共卫生相关性：艰难梭菌相关性疾病（CDAD）是由抗生素治疗引起的，已成为最昂贵和最有害的医院获得性感染。这项SBIR研究建议通过使用抗生素辅助剂来预防CDAD。